Triplet regimen of encorafenib, binimetinib and cetuximab extends survival in BRAF V600E-mutated mCRC
14 Nov 2019
byDr Margaret Shi
The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.
Triplet regimen of encorafenib, binimetinib and cetuximab extends survival in BRAF V600E-mutated mCRC
14 Nov 2019